Driving CAR T-Cell Therapy From Bench to BedsideBiotechin.AsiaScientists first began to experiment with CAR T cells in the late 1980s, when a trio of researchers genetically engineered T cells to express a chimeric T cell receptor fused with a variable… Continue reading
Driving CAR T-Cell Therapy From Bench to BedsideBiotechin.AsiaScientists first began to experiment with CAR T cells in the late 1980s, when a trio of researchers genetically engineered T cells to express a chimeric T cell receptor fused with a variable… Continue reading
Genetic Engineering & Biotechnology News |
Gene Therapy: A New Twist on an Old Helix
Genetic Engineering & Biotechnology News The promise of fixing these genetic blunders of nature with one or a few treatments is close to becoming a reality. Since it was conceptualized in the 1970s, gene therapy has had its ups and downs. In 1990, it was first used to treat a patient. The … |
|
中国学者Nature子刊文章：建立高效的CRISPR-Cpf1基因组编辑系统
生物通 生物通报道：来自中科院上海生科院的研究人员发表了题为“CRISPR-Cpf1 assisted genome editing of Corynebacterium glutamicum”的文章，发现新凶手弗兰西斯菌来源的Cas效应蛋白(FnCpf1)与谷氨酸棒杆菌适配，而 … |
|
Cell, gene therapies are hot. But can this startup make them safer?
San Francisco Business Times Using a cloud-based software platform, San Francisco’s Vineti wants to be the FedEx of cell and gene therapies. Subscribe to get the full story. Already a subscriber? Sign in. Subscribe to get the full story. Already a subscriber? Sign in. SPECIAL … |
|
Cell, gene therapies are hot. But can this startup make them safer?
San Francisco Business Times Using a cloud-based software platform, San Francisco’s Vineti wants to be the FedEx of cell and gene therapies. Subscribe to get the full story. Already a subscriber? Sign in. Subscribe to get the full story. Already a subscriber? Sign in. SPECIAL … |
Hemophilia News Today |
Shire’s Experimental Gene Therapy Delivery Strategies Show Potential for Hemophilia A and B
Hemophilia News Today Shire is developing a potential new strategy to improve the effectiveness of genetic delivery of clotting factor VIII (FVIII) for the treatment of patients with hemophilia A, and clotting factor IX (FIX) for patients with hemophilia B. The most recent … |
The Atlantic |
How CRISPR Yanked Jennifer Doudna Out of the Ivory Tower
The Atlantic But CRISPR forcefully yanked Doudna out of that closeted environment, and dumped her into the midst of intense ethical debates about whether it’s ever okay to change the DNA of human embryos, whether eradicating mosquitoes is a good idea, and whether … Who will pay for CRISPR?STAT 10 Amazing Things Scientists Just Did with CRISPRLive Science Crispr Offers a Leap Forward for Diagnosing DiseaseWall Street Journal (subscription) Technology Networks –BioNews all 11 news articles » |